Arrowhead Pharma ARWR

HealthcareMarket cap $3B2 connections

Arrowhead develops RNAi (RNA interference) therapies - injectable drugs that silence disease-causing genes. Its ARCS platform enables targeted delivery to liver, lung, and muscle tissue. Pipeline targets include NASH/MASH liver disease, pulmonary arterial hypertension, and genetic cardiomyopathy - large markets with inadequate treatments.

Explore Arrowhead Pharma on the interactive map Relationship timeline Find a path to another company

Partners 2

Strategic partnerships, joint products and alliances

Johnson & JohnsonHealthcare · $380BJ&J licenses Arrowhead RNAi platform for liver targets
Alnylam PharmaHealthcare · $25BCompeting RNAi therapeutic companies

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Arrowhead Pharma's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=ARWR" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Arrowhead Pharma on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.